Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Global Meningococcal Vaccines Market to Reach $5.1 Billion by 2027 at a CAGR of 9.25%
By: PR Newswire Association LLC. - 04 Oct 2022Back to overview list

DUBLIN, Oct. 4, 2022 /PRNewswire/ -- The "Meningococcal Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global meningococcal vaccines market size reached US$ 3.0 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 5.1 Billion by 2027, exhibiting a CAGR of 9.25% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.



Meningococcal vaccine refers to a biological substance administered for the prevention of meningitis, which is a contagious infection of the membranes surrounding the spinal cord and the brain. The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines. They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y. Once the vaccine is administered, antibodies are formed to fight the bacteria and create an immune response to prevent the infection in the future.



The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage. In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.



Key Market Segmentation



Breakup by Vaccine Type:

  • Conjugate
  • Polysaccharide
  • Subcapsular

Breakup by Composition:

  • Mono Vaccines
  • Combination Vaccines

Breakup by Vaccine Serotype:

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Breakup by End User:

  • Pediatric
  • Adult

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Key Topics Covered:



1 Preface



2 Scope and Methodology



3 Executive Summary



4 Introduction



5 Global Meningococcal Vaccines Market



6 Market Breakup by Vaccine Type



7 Market Breakup by Composition



8 Market Breakup by Vaccine Serotype



9 Market Breakup by Distribution Channel



10 Market Breakup by End User



11 Market Breakup by Region



12 SWOT Analysis



13 Value Chain Analysis



14 Porters Five Forces Analysis



15 Price Analysis



16 Competitive Landscape



Companies Mentioned

  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/d02x8w

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/global-meningococcal-vaccines-market-to-reach-5-1-billion-by-2027-at-a-cagr-of-9-25-301640403.html

SOURCE Research and Markets

Copyright 2022 PR Newswire Association LLC. Back to overview list
to the top ↑